The Effects of Low Dose Naltrexone (LDN) on Diseases of Aging

AgelessRx

Status: Withdrawn

Conditions: Aging

Treatments: Drug: low-dose naltrexone

Study type: Observational

Funder types: Industry

Identifiers

NCT05307627

ALRx002

Details and patient eligibility

About

This retrospective, observational study will assess the health status of short- and long-term low-dose naltrexone (LDN) users.

Full description

Long-term (>5 years), intermediate-term (1-5 years), and short-term low-dose naltrexone (LDN) users (<12 months) will be contacted for a retrospective, observational assessment of their health status. Participants will be asked to complete a series of questionnaires assessing their quality of life, general physical and mental health, family history, the occurrence of age-related diseases, and immune status. Additionally, blood tests for immune and longevity markers will be optional for a subset of participants.

Sex: All

Ages: 18 to 120 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adults (aged 18-120)
• Any sex
• Any ethnicity
• Taking LDN
• Willing to complete health questionnaires
• Technologically competent to complete web forms
• Subgroup: willing to undergo blood testing

Exclusion criteria

• LDN doses over 20 mg/day
• Terminal cancer patients (defined as stage IV and/or with a life expectancy of 12 months or less)

Trial design

0 participants in 3 patient groups

Long-term (>5 years) LDN users

Description:

Participants who have been using LDN for over 5 years

Treatment:

Drug: low-dose naltrexone

intermediate-term (1-5 years) LDN users

Description:

Participants who have been using LDN for at least 1 year, but shorter than 5 years.

Treatment:

Drug: low-dose naltrexone

short-term (<12 months) LDN users

Description:

Participants who have been using LDN for less than a year. This group will serve as the control group.

Treatment:

Drug: low-dose naltrexone